GDF2: Growth/differentiation factor 2
Potent circulating inhibitor of angiogenesis.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on GDF2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Dalantercept | Phase 3 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Protein or peptide | InhibitorGrowth/differentiation factor 2 inhibitor | 0 |
- Hereditary hemorrhagic telangiectasia0.74
- Heritable pulmonary arterial hypertension0.56
- Hypertensive disorder0.54
- Pulmonary arterial hypertension0.45
- Increased blood pressure0.42
- Cardiovascular disorder0.34
- Abnormality of the cardiovascular system0.19
- Refractive error0.18
- Hepatocellular carcinoma0.14
- Varicose veins0.14
- Neoplasm0.11
- Non-alcoholic fatty liver0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3831181, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9UK05, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets